Calcipotriol

Evidence Level: L3

Predicted Indications: 10

Calcipotriol

Pharmacist Assessment Report

Calcipotriol: From Psoriasis (Topical Vitamin D Analog) to Seborrheic Keratosis

One-Sentence Summary

Calcipotriol is a topical vitamin D3 analog marketed in Canada, mainly in products for plaque psoriasis (the approved indication text is not included in the data compiled for this report). The TxGNN model predicts it may be effective for seborrheic keratosis, with no registered clinical trials and 4 publications (small clinical studies and case reports) currently supporting this direction.

Quick Overview

Item	Content
Original Indication	Not stated in the licence data (calcipotriol products are generally used for psoriasis)
Predicted New Indication	Seborrheic keratosis
TxGNN Prediction Score	0.9996
Evidence Level	L3
Canada Market Status	Marketed (marketed DINs: 6 of 6)
Number of DINs	6 (marketed: 6)
Recommended Decision	Hold (treat as a research question)

Why is This Prediction Reasonable?

Detailed mechanism-of-action data is not available in the data compiled for this report. Based on known pharmacology, calcipotriol is a vitamin D3 analog that acts through the vitamin D receptor (VDR). It inhibits keratinocyte proliferation, promotes differentiation, and induces apoptosis.

Psoriasis and seborrheic keratosis are both skin conditions with abnormal keratinocyte growth. Seborrheic keratosis is a common benign epidermal tumour of older adults. The effects above are therefore plausibly relevant to it. Published reports suggest that apoptosis induction may be the mechanism in senile warts (an older term for seborrheic keratosis).

The evidence is limited to small clinical studies and case reports. The mechanistic link is a hypothesis and has not been confirmed in controlled trials.

Clinical Trial Evidence

Currently no related clinical trials registered.

Literature Evidence

PMID	Year	Type	Journal	Key Findings
36752725	2023	Case series (12 patients)	Australas J Dermatol	0.005% calcipotriol ointment for 3–8 months on solitary facial flat seborrheic keratosis gave complete regression; remission lasted 6–10 years
16043912	2005	Clinical study	J Dermatol	Topical active vitamin D3 (tacalcitol, calcipotriol, maxacalcitol) in 116 senile wart cases over 3–12 months; 35 (30.2%) responded; apoptosis induction suggested
15577148	2004	Clinical report	Clin Calcium	Topical active vitamin D3 ointments applied once or twice daily to senile warts
10721662	2000	Case report	J Dermatol	Marked response of keratosis lichenoides chronica (a related but distinct keratotic disorder) to calcipotriol ointment

Canada Market Information

DIN	Product Name	Dosage Form	Approved Indication
01976133	DOVONEX	Not specified	Not specified
02525178	TARO-CALCIPOTRIOL / BETAMETHASONE GEL	Not specified	Not specified
02319012	DOVOBET GEL	Not specified	Not specified
02427419	TEVA-BETAMETHASONE/ CALCIPOTRIOL	Not specified	Not specified
02457393	ENSTILAR	Not specified	Not specified

A sixth authorization, DOVOBET OINTMENT (DIN 02244126), is also valid. All six are licences with valid status.

Safety Considerations

Package insert warnings and contraindications were not available in the data compiled for this report. Please refer to the package insert for safety information.

The following items come from the TxGNN model (deep learning) and may reflect similarities the model learned between related diseases, not biological evidence, and not from label text:

Possible disease-level contraindication signals: hypercalcemia and other calcium or phosphorus metabolism disorders (including nephrocalcinosis, calcinosis, calciphylaxis, hypervitaminosis), adrenocortical insufficiency/Addison disease, skin atrophy, telangiectasia and other capillary disorders, peripheral vascular disease, and certain ichthyoses and keratinizing disorders (e.g., Darier disease, guttate psoriasis).
Drug Interactions: 84 interactions were recorded, but severity levels are all “Unknown”. Examples include corticosteroids (prednisone, prednisolone, hydrocortisone, triamcinolone), acetylsalicylic acid, doxycycline, simvastatin, metformin, and proton pump inhibitors (omeprazole, pantoprazole, lansoprazole, rabeprazole). Clinical significance needs to be verified.

Conclusion and Next Steps

Decision: Hold (research question)

Rationale: The TxGNN score is very high, and the biological rationale is plausible. The supporting evidence is only small, mostly uncontrolled clinical reports, with no registered trials and no comparative data against standard treatments (cryotherapy, curettage, laser). Safety label data is also missing.

To proceed, the following is needed:

Health Canada package insert warnings, contraindications, and approved indications (currently blocking)
Detailed mechanism of action data (MOA)
A controlled study (ideally randomized) in seborrheic keratosis, compared with standard destructive therapies
Tolerability and local-irritation assessment on facial skin, and calcium monitoring if used over larger areas
Review of the knowledge-graph contraindication signals and interaction severity against the official label

Other predicted indications (ranks 2–10): All carry weak or no direct evidence and are on Hold. Vulvitis and vulvar neoplasm have only indirect or case-level support (via vulvar psoriasis and benign genital acanthomas, respectively). The rest (vulvar inverted follicular keratosis, vulvovaginitis, vulvar ulceration, vulvar squamous neoplasm, postmenopausal atrophic vaginitis, bone Paget disease, breast fibrocystic disease) are computational predictions only, and several raise mucosal-irritation or hypercalcemia concerns.

Disclaimer

This content is for research purposes only and does not constitute medical advice. Clinical validation is required before any clinical application.